Skip to main content

Table 2 Adverse events

From: Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Grade, n% CPB (n = 124) CPA (n = 122) HR (95%) p-value
≥ 2 genitourinary fistula 0 (0) 0 (0) NA 1.000
≥ 2 gastrointestinal fistula 0 (0) 0 (0) NA 1.000
≥ 3 gastrointestinal bleeding 0 (0) 0 (0) NA 1.000
≥ 2 hypertension 31 (25.0) 5 (4.1) 7.00 (4.52–6.02) < 0.001*
≥ 4 neutropenia 42 (33.9) 18 (14.8) 4.00 (3.83–5.36) < 0.001*
≥ 3 thrombosis/embolism 11 (8.9) 3 (2.5) 2.00 (1.48–3.71) 0.030*
≥ 2 pain 38 (30.6) 34 (27.9) 3.00 (0.14–4.23) 0.633
  1. *Statistically significant. CPB cisplatin-paclitaxel chemotherapy plus bevacizumab, CPA cisplatin-paclitaxel chemotherapy alone, HR Hazard ratio, NA not applicable